FUJIFILM Holdings Corp · TSE:4901
FUJIFILM — Investor Presentation (April 2021)
35 slides from FUJIFILM's investor presentation, Apr 15, 2021
Slide 1: Medium-Term Management Plan VISION 2023
Medium-Term Management Plan VISION 2023 April 15, 2021 Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management’s current assumptions and beliefs based on currently available information. Such forward-looking statements
Slide 2: Our Ideal Fujifilm Vision
Our Ideal Fujifilm Vision Using leading-edge, proprietary technologies to provide top-quality products and services, we will strive Sustainable to “resolve social issues through our Value Plan business activities” and contribute to 2030 the realization of a sustainable society. (SVP2030) VISION 2023
Slide 3: Looking Back on VISION 2019
Looking Back on VISION 2019 VISION 2019 Management Policy Positioning each business into one of three stages: improve profitability, accelerate further growth, and invest to create a new future. Strengthen our business portfolio and inspire further leaps forward by developing measures to suit that g
Slide 4: Looking Back on VISION 2019: Priority Issues
Looking Back on VISION 2019 VISION 2019 Priority Issues Priority Issues Measures Acquired Biogen (Denmark) Decided large -Reorganization- Accelerate Acquired Wako Acquired Manufacturing capex into bio Further growth in Pure Chemical Irvine Decided acquisition of CDMO accelerate healthcare field Indu
Slide 5: Financial Targets in VISION 2023
Financial Targets in VISION 2023 (Billions of yen) FY2020 FY2021 FY2023 Change from forecast VISION2023 VISION2023 FY2020 Revenue 2,180.0 2,440.0 2,700.0 520.0 100% 100% 100% +23.9% Operating Income 185.0 215.0 270.0 85.0 before One-time Costs 8.5% 8.8% 10.0% +45.9% One-time Costs 25.0 35.0 10.0 (15
Slide 6: Resolution of Social Issues through Business Activities
Resolution of Social Issues through Business Activities Priority Areas Segments SDGs Goals Healthcare ・Countermeasures to climate change. Enviro- ・Promote recycling of resources. Materials nment ・Address energy issues. Business Innovation ・Ensure product and chemical safety. Imaging •Create a health
Slide 7: Initiatives for Environment related Issues through Business Activities
Initiatives for “Environment” related Issues through Business Activities Achieved original 30% reduction target by FY2019. Enviro- Countermeasures to climate change Revised target up to 45%. nment Received SBT*3 well below 2℃*4 certification. *3 Science Based Targets initiative *4 well-below2℃ ▶Targ
Slide 8: Initiatives for Health and Work Style related Issues
Initiatives for “Health” and “Work Style” related 「環境」課題への取り組み Issues through Business Activities Setting new KPIs in the areas of “Health” and “Work Style”. Improve medical accessibility by introducing our AI-driven Health medical products and services to all countries and regions by FY2030. 57 100
Slide 9: VISION 2023: Basic Concept
VISION 2023: Basic Concept Accelerate Healthcare & Materials growth. Build more resilient business platform to facilitate sustainable growth. ・Secure growth investment capital. ・Concentrate management resources on new/future potential and growth driver businesses. ・Accelerate/strengthen cash generat
Slide 10: Business Portfolio Management
Business Portfolio Management Inject ¥1.2 trillion growth investment* over 3 years, with ¥1.0 trillion channeled into new/future potential and growth driver areas. *Total R&D investment and capex for FY2021–FY2023 Drive medium-term High Sow long-term seeds growth/profitability New/future potential G
Slide 11: Segment Reorganization
Segment Reorganization Reorganized into 4 business segments: Healthcare, Materials, Business Innovation, Imaging ■Medical Systems ■Life Sciences ■Bio CDMO ・Life Sciences (drug discovery support : iPS cells, Healthcare cell culture media, reagent) ・Pharmaceutical ・Consumer Healthcare (cosmetics, supp
Slide 12: Business Portfolio Linked with Unique Technologies
Business Portfolio Linked with Unique Technologies Healthcare Materials Business Imaging Innovation Unique technologies advanced while we diversified our operations based on the technologies cultivated in photographic business 11
Slide 13: Cash Flow Management & Shareholder Returns
Cash Flow Management & Shareholder Returns Cash Flow Management ・ Sales/OP growth, plus strengthen total cash output to improve ROIC & CCC* ROIC FY2020(E) 4.2％ → FY2023 target 6.1％ CCC FY2020(E) 125 days → FY2023 target 103 days *Cash conversion cycle ＝ Inventory turnover days + Operating receivable
Slide 14: New Management Structure
New Management Structure Launch new management structure upon approval by June General Shareholdersʼ Meeting and Board of Directors. New Position Current Position Shigetaka Chairman and CEO, Executive Advisor Komori Representative Director Chairman, Representative President and COO, Kenji Sukeno Dir
Slide 15: Business Strategies
Medium-Term Management Plan VISION 2023 Business Strategies 14
Slide 16: Financial Targets by Segment
Financial Targets by Segment (Billions of yen) FY2020 FY2021 FY2023 Change from Revenue*1 forecast VISION2023 VISION2023 FY2020 Healthcare 550.0 750.0 860.0 310.0 (+56.4%) Materials*2 570.0 600.0 720.0 150.0 (+26.3%) Business Innovation*2 780.0 800.0 820.0 40.0 (+5.1%) Imaging 280.0 290.0 300.0 20.0
Slide 17: Financial Target: Further Growth in Healthcare
Financial Target : Further Growth in Healthcare Healthcare to be the largest segment both in revenue and operating profit* 11% 13% 32% 25% FY2020 30% FY2023 36% Revenue Revenue 26% Healthcare Materials 27% Business Innovation Imaging 8% 6% 34% 30% 27% FY2020 FY2023 OP OP 37% 27% 31% 16 *OP excluding
Slide 18: Healthcare
Healthcare ▶Redefine priority areas & restructure the organization • Categorize healthcare into medical systems and Life Sciences (covering Bio CDMO, drug discovery support and such), with Life Sciences Strategy Headquarters established to oversee life sciences field. • In life sciences, make CDMO a
Slide 19: Healthcare (Medical Systems)
Healthcare (Medical Systems) Create a healthy society through providing advanced Health products and services globally in all areas of prevention, diagnosis, and treatment to reduce health disparities. CO２ Emissions by Segment Business Medical Systems business Imaging Innovation Materials Healthcare
Slide 20: Healthcare (bio CDMO, Life Sciences)
Healthcare (bio CDMO, Life Sciences) Bio CDMO business Help improve medical accessibility and fulfill unmet medical needs through stable supply of high-quality biopharmaceuticals and process development and contract manufacture of gene therapeutics, an advanced medical field. • Respond to rapidly ex
Slide 21: Healthcare (Pharmaceutical, Consumer Healthcare)
Healthcare (Pharmaceutical, Consumer Healthcare) Pharmaceutical business Help further develop the pharmaceutical industry by utilizing our unique DDS* technology, manufacturing facilities, and infrastructure. • Promote liposomal formulation development using our nano-dispersion, analysis, and proces
Slide 22: Materials (Highly Functional Materials)
Materials (Highly Functional Materials) Contribute to creating a safe and secure society Daily by developing and providing advanced functional Life materials in the era of promoting DX. CO２ Emissions by Segment ▶Highly Functional Materials Business Imaging Innovation Materials Healthcare Electronic
Slide 23: Materials (Highly Functional Materials)
Materials (Highly Functional Materials) Display Materials business Create timely new products to suit changing market environments by utilizing our wide-ranging technical capabilities that can also be used for next-generation displays. ・Extend materials (anti-reflection film) for organic EL that hav
Slide 24: Materials (Graphic Communication)
Materials (Graphic Communication) ▶ Redefine priority areas, restructure an organization • Fujifilmʼs Graphic Systems Business Div. and FUJIFILM Business Innovationʼs Graphic Communication Service Business Group will be integrated into the Graphic Communication Div. as of July 1, 2021. • Develop one
Slide 25: Imaging
Imaging Contribute to enriching humanity and peaceful life by Daily developing and providing high-quality and high-performance Life products and services in picture and imaging field. ▶ Redefine priority areas, restructure an organization ・The Photo Imaging Products Div. and the Optical Device & CO２
Slide 26: Business Innovation
Business Innovation Contribute to a social change where people feel motivated to work Work through providing products and solution services worldwide that Style increase productivity and inspire creativity. ▶Accelerate global development CO２ Emissions by Segment Business Innovation Imaging • Invigor
Slide 27: Business Innovation
Business Innovation ▶Accelerate growth by further strengthening solution services Enhance document management and cloud 1. Improve collaboration using multifunction devices with productivity derived strong security as gateways from multifunction (Docuworks/Working Folder/Inter-company Working Folder
Slide 28: 27
27
Slide 29: Appendices
Medium-Term Management Plan VISION 2023 Appendices 28
Slide 30: Looking Back on VISION 2019: SVP 2030 Goals and Results
Looking Back on VISION 2019 SVP 2030: Main Goals and Activity Results Priority Areas Priority Issues FY2030 Targets Activity Results Reduce Fujifilm Group CO2 emission Achieved the 30% reduction target ahead of levels by 30% by FY2030 schedule. (compared to FY2013 level). →Revised FY2030 target up t
Slide 31: Change in Segments for Disclosure
Change in Segments for Disclosure <Current Segment> <New Segment> Healthcare & Material Solutions Healthcare Healthcare Medical Systems business Medical Systems business Bio CDMO business Bio CDMO business Life Sciences Regenerative Medicine business Life Sciences business Pharmaceutical business Ph
Slide 32: ROIC, Depreciation & Amortization
ROIC, Depreciation & Amortization ROIC* FY2020 FY2021 FY2023 forecast VISION2023 VISION2023 Healthcare 3.5% 4.3% 5.3% Materials 8.1% 8.2% 12.9% Business Innovation 8.8% 9.1% 10.6% Imaging 6.1% 7.0% 12.1% *ROIC (by segment) = NOPAT/ (working capital + fixed assets) Consolidated total 4.2% 4.6% 6.1% *
Slide 33: CAPEX & R&D Expenses
CAPEX & R&D Expenses CAPEX & R&D Expenses cumulative total (FY2021 - FY2023) (Billions of yen) R&D Capex Total Expenses Healthcare 450.0 144.0 594.0 Materials 110.0 125.0 235.0 Business Innovation 120.0 114.0 234.0 Imaging 40.0 27.0 67.0 Corporate Expenses & Eliminations 30.0 80.0 110.0 Total 750.0
Slide 34: Corporate Philosophy & Vision
Corporate Philosophy & Vision ■ Fujifilm Group Corporate Philosophy We will use leading-edge, proprietary technologies to provide top- quality products and services that contribute to the advancement of culture, science, technology and industry, as well as improved health and environmental protectio
Slide 35: Corporate Communications Div.
At Fujifilm, we are continuously innovating — creating new technologies, products and services that inspire and excite people everywhere. Our goal is to empower the potential and expand the horizons of tomorrow’s businesses and lifestyles. Corporate Communications Div. https://holdings.fujifilm.com/
Fujifilm Holdings — Investor Presentation (April 2021) on 6ix